Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212986 | 0.88 | SMN1; SMN2 (0.41) | TXNRD1NOS1SMN1; SMN2 | |
| SCHEMBL1085712 | 0.72 | HTR1A (0.39) | SMN1; SMN2 | |
| SCHEMBL22481778 | 0.70 | SMN1; SMN2 (0.43) | TXNRD1NOS1SMN1; SMN2 | |
| SCHEMBL9095722 | 0.69 | NOS1 (0.46) | TXNRD1NOS1SMN1; SMN2 | |
| SCHEMBL30760210 | 0.67 | CA1 (0.43) | — | |
| SCHEMBL1464870 | 0.67 | ALDH1A1 (0.38) | TXNRD1NOS1SMN1; SMN2 | |
| SCHEMBL23568545 | 0.66 | ALDH1A1 (0.31) | — | |
| SCHEMBL23531799 | 0.66 | TXNRD1 (0.33) | TXNRD1NOS1SMN1; SMN2 | |
| SCHEMBL1465766 | 0.65 | ALDH1A1 (0.36) | TXNRD1SMN1; SMN2 | |
| SCHEMBL5329734 | 0.65 | CCR4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2305641-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | TXNRD1 1157/4885NOS1 1722/4885SMN1; SMN2 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.